Flexibility And Scientific Innovation In Oral Solid Dose (OSD) Development At Our Bend, Oregon Site

Early-stage biotech drug development is rarely predictable. Formulation optimization, process development, and stability studies can quickly become critical path activities — creating delays and forcing decisions that can shape the long-term success of a program.

Moving a drug development program forward takes more than scientific expertise. It takes a CDMO partner that is proactive, adaptable, and committed to helping you navigate challenges, respond to changing priorities, and keep your program on track.

Cerevance, a Boston-based clinical-stage biotech company, experienced these challenges firsthand with a complex oral solid dose program. By partnering with Thermo Fisher Scientific’s site in Bend, Oregon, the Cerevance team was able to overcome formulation challenges, adapt as program priorities evolved, and tap into an integrated global network to maintain momentum throughout development.

In this four-part video series, hear directly from Cerevance leaders as they share how a collaborative CDMO partnership helped keep development moving forward, address challenges proactively, and build confidence at every stage.